Royal Bank of Canada Invests $8.73 Million in Haleon plc (NYSE:HLN)

Royal Bank of Canada acquired a new position in Haleon plc (NYSE:HLN – Get Rating) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,432,878 shares of the company’s stock, valued at approximately $8,725,000.

Other hedge funds have also made changes to their positions in the company. Fifth Third Bancorp purchased a new position in shares of Haleon in the third quarter valued at $66,000. Gilman Hill Asset Management LLC purchased a new position in shares of Haleon in the third quarter valued at $426,000. Crossmark Global Holdings Inc. purchased a new position in shares of Haleon in the third quarter valued at $1,642,000. Janiczek Wealth Management LLC purchased a new position in shares of Haleon in the third quarter valued at $83,000. Finally, Stratos Wealth Partners LTD. acquired a new stake in shares of Haleon during the third quarter valued at $118,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of NYSE HLN opened at $7.68 on Friday. The business’s 50-day moving average price is $7.96 and its two-hundred day moving average price is $7.05. Haleon plc has a one year low of $5.59 and a one year high of $8.50.

Haleon Announces Dividend

The firm also recently disclosed a — dividend, which will be paid on Thursday, April 27th. Investors of record on Friday, March 17th will be given a dividend of $0.0577 per share. The ex-dividend date of this dividend is Thursday, March 16th. This represents a dividend yield of 0.7%.

Analysts Set New Price Targets

A number of brokerages have issued reports on HLN. Morgan Stanley raised Haleon from an “equal weight” rating to an “overweight” rating in a research note on Friday, January 6th. Barclays raised their price target on Haleon from GBX 360 ($4.33) to GBX 364 ($4.38) in a research note on Tuesday, January 31st. Finally, Investec began coverage on Haleon in a research note on Thursday, February 23rd. They issued a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $364.00.

Haleon Company Profile

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.